Global fibrinolytic cdpucity increased exponentially in metastatic colorectal cancer

Kockar C., Kockar O., Ozturk M., Dagli M., Bavbek N., Kosar A.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.11, no.2, pp.227-230, 2005 (SCI-Expanded) identifier identifier identifier


Colorectal cancers are one of the most common malignancies associated with coagulation abnormalities ranging from asymptomatic laboratory changes to massive thromboembolism or hemorrhage. It was previously shown that global fibrinolytic was increased in non-metastatic colorectal cancer. In this study global fibrinolytic capacity was measured in patients with colorectal cancer and metastatic liver disease, which always more commonly displays. various coagulation disorders. Nineteen patients with biopsy-proven colorectal cancer, 30 patients with metastatic colorectal cancer, and 20 healthy control subjects were involved into the study. Using standart silicated fibrin pellets and tissue plasminogen activator, fibrinolytic capacity of the plasmas was detected with the amount of D-dimer produced before the reaction was stopped by adding aprotinin to the medium. Mean global fibrinolytic capacity (GFC) was increased to higher levels in patients with metastatic disease compared to levels in non-metastatic disease (p < 0.05). Fibrinogen/GFC ratio correlated to the increase Of D-dimer levels. Global fibrinolytic capacity was much higher in metastatic disease, reflecting a progression to overt disseminated intravascular coagulation.